Using EMRs to improve monitoring of long-term clinical trial outcomes

Researchers from Swansea University Medical School and the College of Human and Health Sciences have used electronic medical records (EMRs) to improve clinical trials by expanding remote monitoring. Findings were published May 16 in Scientific Reports.

Currently, clinical trials may face pressure to be completed in a short time due to limited resources, limiting their ability to track long-term outcomes. In this study, researchers evaluated the impact in using EMRs to follow up with patients after trial participation.

 

Using the Secure Anonymized Information Linkage (SAIL) databank at Swansea University Medical School, researchers evaluated the feasibility of using anonymized EMR data to match patients to their records. This study evaluated SAIL in a clinical trial to examine the impact of the use probiotics during pregnancy on asthma and eczema in children.

"SAIL is a world-class, privacy-protecting data linkage system that securely brings together routinely-collected health data,” said SAIL Associate Professor Kerina Jones, the academic lead for data governance and public engagement. “SAIL is part-funded by the Welsh Government and makes person-based health data available for genuine research purposes only where there is a potential for benefit. Because SAIL removes the identities of participants to protect their privacy and holds only anonymized data, researchers carry out their work without knowing the identities of the individuals."

Results showed SAIL was able to improve retention of lower socio-economic groups, produce more reliable results due to lowered risk of bias, provide insight into childhood asthma and boost retention after five years.

"In this study we reported on the feasibility and efficiency of electronic follow up, and compared it with traditional trial follow up,” said Professor Sue Jordan of Swansea University's College of Human and Health Science. “We gained new insights from outcomes electronically recorded three years after the end of the trial and could then identify the differences between trial data and electronic data. The use of electronic databases in clinical trials has been hailed as one of the major benefits of a nationwide electronic health records system. However, few studies have demonstrated this benefit, or formally assessed the relationship between traditional trial data and electronic health records databases."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.